Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

9.6 million SEK allocated for research on dogs, cats and other small pets

Are you interested in understanding the emotional bond between dog owners and their puppies or aging dogs? Perhaps you want to know whether the size of a puppy litter can serve as an indicator of a breed's health. Ten new research projects, recipients of funding from the Agria SKK Research Fund for 2024, are set to commence soon. These research initiatives, concentrating on dogs, cats, and other small pets, are conducted across Sweden, Norway, Denmark, Finland, and Germany. In total, there are 10 new projects and 9 ongoing ones, collectively sharing 9.6 million SEK. This year,

Invitation to presentation and Q&A of year end report 2023

Göteborg, Sweden — 31 January, 2024. Sleep Cycle AB (publ), the world’s leading sleep tracking application, will on the 8th of February, at 9:30 CET, present the year end report 2023 for shareholders, media and other stakeholders. Participants will be able to follow the presentation via webcast.Sleep Cycles CEO Erik Jivmark and CFO Per Andersson will present the report, which will be followed by a Q&A session. The presentation will be held in English. Link to webcast: https://ir.financialhearings.com/sleep-cycle-q4-2023 If you wish to participate via teleconference, please register on

Number of shares and votes in Medicover

The number of shares and votes in Medicover AB (publ) (“Medicover” or the “company”) has changed as a result of conversions of in total 6,975 class A shares into B shares carried out in January following requests from shareholders in accordance with the conversion clause in Medicover’s articles of association. Today, the last trading day of the month, there are in total 153,535,195 shares in Medicover, of which 76,664,401 are class A shares, together carrying 76,664,401 votes, 72,987,972 are class B shares, together carrying 7,298,797.2 votes and 3,882,822 are class C shares, together

First patient using Zeqmelit® in study ahead of market launch

The first patient in the AcuCort Phase IV study ZEQ001 has been assigned the oral film Zeqmelit®. The purpose of the study is to enhance marketing with practical experience from doctors and patients in connection with the launch in the Nordic region.The study will run concurrently with the Nordic market launch. In the study, allergy patients are assigned the company’s oral film Zeqmelit® for use when the need for treatment for acute allergic reactions arises. The goal of the study, which is an open-label non-randomized low-intervention study, is to obtain valuable data on the use of

Thinkproject appoints new non-executive Board Members: Darren Roos and Constance Minc; Darren Roos becomes new Chairperson

New board additions to accelerate Thinkproject’s expansion and growth plansPress release Munich, 31st January 2024 – Thinkproject, Europe’s leading SaaS platform for digital construction and asset management solutions, announces the appointment of two highly seasoned executives and industry leaders to its Board. The non-executive appointments of Darren Roos and Constance Minc will accelerate the company’s international expansion and growth aspirations.   Darren Roos will assume the role of Chairperson of the Board at Thinkproject. Roos is a proven enterprise software leader with a

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 26 - 31 JANUARY 2024   In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 186/23 and 187/23.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

BioStock: Evaxion to develop novel precision cancer vaccine concept

Evaxion Biotech has announced an expanded commitment to developing precision cancer vaccines by targeting a novel category of tumour antigens called endogenous retroviruses (ERVs). These will be identified with the company’s proprietary target discovery AI-Immunology platform, and proof-of-concept data is expected later this year.Read the article at biostock.se: Evaxion to develop novel precision cancer vaccine concept - BioStock This is a press release from BioStock - Connecting Innovation &

PONSSE Manager 2.0 gathers digital offering into one package

PONSSE Manager 2.0. is a next-generation digital service platform and forest machine management system that provides customers valuable data of machines’ location, productivity figures and fuel consumption, among others. The PONSSE Manager monitors the progress of stands, plans, and manages machine transportation, keep track of machine outputs according to assortment and print out measuring certificates."With the quick tempo of the modern world and the huge amount of data we see every day, finding the correct piece of information is often like trying to find a needle in the haystack. New

BioStock: Saniona raises capital to advance epilepsy programme

Saniona’s CEO Thomas Feldthus visited BioStock’s studio for an interview discussing the company’s drug development pipeline with epilepsy candidate SAN711 leading the way. We also learn more about the ongoing rights issue of approximately SEK 140 million and how Saniona plans on using the proceeds.Watch the interview with Saniona's CEO Thomas Feldthus at biostock.se: Saniona raises capital to advance epilepsy programme - BioStock This is a press release from BioStock - Connecting Innovation &

Alleima receives a major order for advanced tubes; umbilicals for the Oil and Gas segment

Alleima has received a major order for advanced tubes; umbilicals, for the Oil and Gas customer segment, to a total value of approximately SEK 520 million.The order is valued to approximately SEK 520 million will be used for an offshore project in South America. It is classified as a major order (i.e. above SEK 200 million) and will be reported in the Tube division. The order was booked in the first quarter of 2024 and deliveries are scheduled between the end of 2024 and the beginning of 2025. “Once again Alleima is chosen as a trusted supplier for high value-added products, umbilical

Akastor ASA: Invitation to presentation of fourth quarter results 2023

Akastor ASA invites investors and analysts to a webcast presentation of fourth quarter 2023 financial results on Wednesday 14 February. Date and time:Wednesday 14 February 2024 at 15:00 CET Presenters:Akastor - Karl Erik Kjelstad, CEO and Øyvind Paaske, CFOHMH – Eirik Bergsvik, CEO and Thomas McGee, CFO Link to webcast:https://channel.royalcast.com/landingpage/hegnarmedia/20240214_10/ Questions can be submitted throughout the streaming event. The presentation material will be published at www.akastor.com and www.newsweb.no at 07:00 CET on 14 February. For further

21ST.BIO OPENS A MORE SUSTAINABLE AVENUE FOR INDUSTRIAL SCALE DAIRY PROTEIN PRODUCTION

· Global bioproduction leader 21st.BIO today announced it is now granting access to its precision fermentation technology platform to food and ingredient manufacturers, enabling sustainable production of dairy proteins at competitive cost. · Access to 21st.BIO’s technology represents a step change to food production with precision fermentation, allowing manufacturers to focus on production, product development and commercialization.     · 21st.BIO offers the most advanced production strains, best end-product quality, exclusive know-how, and considerable savings in time and resources

Invitation to presentation of MilDef´s year-end and fourth quarter report 2023, on February 8

MilDef, a leading supplier of tactical IT, software solutions and services, will publish its year-end and fourth quarter report 2023 on February 8, at 08:00 am CET.A conference (on Teams) for investors, analysts and media will be held at 10.00-10.45 CET that same day. The report will be presented by Daniel Ljunggren, CEO and CFO Viveca Johnsson.  The presentation will be held in English and is concluded with a Q&A session, moderated by Olof Engvall, Head of Investor Relations. Presentation material will be made available on www.mildef.com the same morning. Notification is not required

Volvo introduces its first ever electric-only truck– optimized for cleaner and safer city transports

Volvo launches its first truck model ever developed only with electric drive. With capacity for heavy loads and excellent visibility for the driver, FM Low Entry is an electric truck optimized for safe and efficient driving in city areas.      Volvo Trucks’ latest addition to its electric truck program – Volvo FM Low Entry – is a heavy-duty truck specifically developed to handle a wide variety of transport assignments in city areas.As more and more cities aim to improve their city environments by lowering emission levels, demand is rapidly rising for zero-exhaust emission trucks

Cereno Scientific is granted Expanded Access by the FDA to drug candidate CS1 for rare disease pulmonary arterial hypertension

Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that the company has been granted approval by the FDA for Expanded Access, sometimes called “compassionate use”, to investigational drug CS1 for use in an extension of the ongoing Phase II trial evaluating CS1 in pulmonary arterial hypertension (PAH). Cereno’s Expanded Access Program (EAP) to drug candidate CS1 will initially be limited to patients who have completed the Phase II study in PAH. The approval of the Expanded Access Program (EAP)

BioStock: Alligator meets primary endpoint with CD40 agonist in pancreatic cancer

Alligator Bioscience has released positive top-line data from the phase II trial assessing the efficacy of the CD40 agonist mitazalimab in pancreatic cancer. Having met the primary endpoint, the company can now start preparing for phase III. Alligator's CEO Søren Bregenholt stopped by the BioStock studio in Lund to give us a rundown of the results.Watch the interview with Alligator Bioscience's CEO Søren Bregenholt at biostock.se: Alligator meets primary endpoint with CD40 agonist in pancreatic cancer - BioStock 

Eventful year ends with record cash flow

“In summary, we closed an eventful 2023 in which we grew sales by 42 per cent and EBITA, excluding items affecting comparability, by 53 per cent. Sales during the quarter amounted to SEK 7,627 million, which is an increase of 31 per cent compared with the corresponding period the previous year. EBITA before items affecting comparability amounted to SEK 721 million, which is an increase of 26 per cent compared to the corresponding period the previous year. The EBITA margin, excluding items affecting comparability, was 9.5 per cent compared with 9.8 per cent the previous year. There was a

Invitation to the presentation of Ratos Year-end report 2023

The Year-end report 2023 will be released on Monday 12 February at 07.00 CET.At 09.00 CET will Jonas Wiström, President and CEO, and Jonas Ågrup, CFO, present the report.The presentation can be followed on Youtube via the following link; https://youtube.com/live/7Hg1raV2EpQ?feature=shareThe live presentation will be recorded and is available afterwards via the same link.Participants who wish to ask questions live are asked to pre-register, please send an e-mail to helena.jansson@ratos.com in advance for a personal invitation.The presentation and report will be available on www.ratos.

The Nomination Committee's proposal for Board of Directors of Indutrade AB for the 2024 AGM

The Nomination Committee proposes re-election of Katarina Martinson as Chair of the Board at the 2024 Annual General Meeting. The Committee also proposes the re-election of Board members Bo Annvik, Susanna Campbell, Anders Jernhall, Kerstin Lindell, Ulf Lundahl and Lars Pettersson. Krister Mellvé has announced that he is not available for re-election. Pia Brantgärde Linder is proposed to be elected as new Board member. Pia Brantgärde Linder, born 1973, has a Master of Science in Mechanical Engineering from Chalmers University of Technology and an Executive Master of Business

Elisa establishes a new share-based incentive plan for key employees

ELISA CORPORATION STOCK EXCHANGE RELEASE 31 JANUARY 2024 AT 9:30 AMThe Board of Directors of Elisa Corporation has resolved to establish a new share-based incentive plan for key employees of the group. The purpose of the plan is to align the interests of the company’s shareholders and key employees to increase the company’s value in the long-term, to commit key employees to implement the company's strategy, objectives and long-term interest and to offer them a competitive incentive plan based on earning and accumulating the company´s shares. The Performance-based Share Plan 2024–2028

Number of shares and votes in Medivir AB on 31 January 2024

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during January 2024 as a result of the rights issue resolved on by Medivir on 7 November 2023 and the directed issue to Hallberg Management AB resolved on by Medivir on 22 January 2024. Both issues have been previously announced through separate press releases. The new issues resulted in an increase of 48,664,647 ordinary shares respectively 7,547,170 ordinary shares, which entails an increase of 56,211,817 ordinary shares in total.   Today, the last

Repurchase of Outokumpu’s own shares

Outokumpu OyjStock exchange releaseJanuary 31, 2024 at 9.30 am EETRepurchase of Outokumpu’s own shares On January 30, 2024, Outokumpu has completed repurchases of its own shares as follows (ISIN FI0009002422): +-------+----------------+------------------------------------+----------------+|Trading|Number of shares|Weighted average price / share, EUR*|Total cost, EUR*||venue | | | |+-------+----------------+------------------------------------+----------------+|CEUX |59,315 |4.0012

Correction: DNB Bank ASA – proposed cash dividend for 2023 - key information

The Board of Directors of DNB Bank ASA plans to propose to distribute a cash dividend of NOK 16.00 per share for the accounting year of 2023. The formal decision regarding the dividend will be made on the company’s Annual General Meeting, which will be held on 29 April 2024. Dividend amount: 16.00 per share Declared currency: Norwegian krone (NOK) Last day including right: 29 April 2024 Ex-date: 30 April 2024Record date (shareholder registration date): 2 May 2024Payment date: from 8 May 2024Date of approval: 29 April 2024 This information is published in accordance with

There are no items matching the current filter
There are no more items matching the current filter
Back to top